- Home
- COSM vs SONN Comparison
COSM vs SONN Comparison
Compare COSM & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COSM
- SONN
- Stock Information
- Founded
- COSM 2009
- SONN N/A
- Country
- COSM United States
- SONN United States
- Employees
- COSM N/A
- SONN N/A
- Industry
- COSM Other Pharmaceuticals
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- COSM Health Care
- SONN Health Care
- Exchange
- COSM Nasdaq
- SONN Nasdaq
- Market Cap
- COSM 32.3M
- SONN 32.4M
- IPO Year
- COSM 2013
- SONN N/A
- Fundamental
- Price
- COSM $0.75
- SONN $5.82
- Analyst Decision
- COSM
- SONN Strong Buy
- Analyst Count
- COSM 0
- SONN 1
- Target Price
- COSM N/A
- SONN $20.00
- AVG Volume (30 Days)
- COSM 462.3K
- SONN 715.1K
- Earning Date
- COSM 11-14-2025
- SONN 12-16-2025
- Dividend Yield
- COSM N/A
- SONN N/A
- EPS Growth
- COSM N/A
- SONN N/A
- EPS
- COSM N/A
- SONN N/A
- Revenue
- COSM $55,093,442.00
- SONN $1,000,000.00
- Revenue This Year
- COSM $28.14
- SONN $5,376.22
- Revenue Next Year
- COSM N/A
- SONN N/A
- P/E Ratio
- COSM N/A
- SONN N/A
- Revenue Growth
- COSM N/A
- SONN 1689.52
- 52 Week Low
- COSM $0.28
- SONN $1.08
- 52 Week High
- COSM $1.32
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- COSM 37.07
- SONN 60.28
- Support Level
- COSM $0.70
- SONN $3.72
- Resistance Level
- COSM $0.77
- SONN $5.14
- Average True Range (ATR)
- COSM 0.08
- SONN 0.90
- MACD
- COSM -0.01
- SONN 0.15
- Stochastic Oscillator
- COSM 21.30
- SONN 100.00
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.